BRAF and cancer: Dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, work synergistically to inhibit the Mitogen-Activated Protein Kinase/Extracellular signal-Regulated Kinase (MAPK/ERK) pathway, which is crucial for the growth and survival of BRAF-mutant cancer cells [7].